knowledge -WSS

knowledge

author：comprehensive 2025-10-02 19:38:56 - browse：44758

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

WSS

CDC picks Alphabet's Verily for wasterwater surveillance contract

House transparency, PBM reform bill gains bipartisan support

Experts study whether long Covid risk adds up with each reinfection

The (many) problems with a new study criticizing cancer screening

How to protect patients from sexual assault

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

Setback for rare diseases as Taysha Gene Therapies pulls back

Medicare details structure of new drug price negotiation program

Medicaid rebukes states for mistakenly disenrolling children

Cancer drug shortages should be causing more outrage

The 10 drugs up first for Medicare price negotiation

23andMe had bad news about my health. I wish a person had delivered it

A rare thyroid diagnosis led to unexpected, all

State Dept. review finds Biden bears some blame for Afghanistan failures

RSV injection headlines need to be accurate for good uptake

explore

The 10 drugs up first for Medicare price negotiation

The 10 drugs up first for Medicare price negotiation

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Stop Congress from blocking public access to science

Illumina names Agilent executive as new CEO

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

leisure time

hotspot

hotspot

knowledge